Cyclophosphamide
Cyclophosphamide, Cytoxan (cyclophosphamide) is a small molecule pharmaceutical. Cyclophosphamide was first approved as Cytoxan on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, BCR-ABL positive chronic myelogenous leukemia, breast neoplasms, burkitt lymphoma, and endometrial neoplasms amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 4 more
Trade Name
FDA
EMA
Cyclophosphamide, Cytoxan (discontinued: Cyclophosphamide, Cytoxan (lyophilized), Neosar)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cyclophosphamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CYTOXAN | Baxter | N-012141 RX | 1982-01-01 | 2 products, RLD |
| CYCLOPHOSPHAMIDE | Baxter | N-217651 RX | 2023-06-28 | 2 products, RLD, RS |
| CYCLOPHOSPHAMIDE | Dr Reddys Laboratories | N-212501 RX | 2020-07-30 | 3 products, RLD, RS |
| CYCLOPHOSPHAMIDE | Dr Reddys Laboratories | N-210852 RX | 2023-06-07 | 3 products, RLD, RS |
| CYCLOPHOSPHAMIDE | Eugia Pharma Specialties | N-210735 RX | 2021-08-25 | 3 products, RLD, RS |
| CYCLOPHOSPHAMIDE | Hikma Pharmaceuticals | N-203856 RX | 2013-09-16 | 2 products, RLD, RS |
| CYCLOPHOSPHAMIDE | Sandoz | N-217150 RX | 2023-09-12 | 3 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cyclophosphamide | New Drug Application | 2050-01-04 |
Indications
FDA
EMA
Show 18 more
Agency Specific
FDA
EMA
No data
Clinical
Clinical Trials
4932 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | 1 | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 2 | — | — | 2 |
| Mucinous adenocarcinoma | D002288 | — | — | — | — | 1 | — | — | 1 |
| Ductal carcinoma breast | D018270 | — | — | — | — | 1 | — | — | 1 |
| Inflammatory breast neoplasms | D058922 | — | — | — | — | 1 | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | 1 | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | — | — | — | 1 | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | — | 1 | — | — | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hodgkin disease | D006689 | — | C81 | 1 | 1 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cyclophosphamide |
| INN | cyclophosphamide |
| Description | Cyclophosphamide is a phosphorodiamide that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by two 2-chloroethyl groups at the amino nitrogen atom. It has a role as a carcinogenic agent, an alkylating agent, an immunosuppressive agent, an antineoplastic agent, an antirheumatic drug, an environmental contaminant, a xenobiotic and a drug allergen. It is a phosphorodiamide, a nitrogen mustard and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O.O=P1(N(CCCl)CCCl)NCCCO1 |
Identifiers
| PDB | — |
| CAS-ID | 6055-19-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200796 |
| ChEBI ID | 4026 |
| PubChem CID | 2907 |
| DrugBank | DB00531 |
| UNII ID | 6UXW23996M (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cyclophosphamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 40,016 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
150,346 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use